Clinical Trial

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

Name: BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. — clinical trial record (NCT07605429)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Purpose of the study is to evaluate the efficacy and safety of intrathecally administered rugonersen in pediatric and adult participants with Angelman syndrome.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-29

Trial Details

NCT Number	NCT07605429
Lead Sponsor	OHB Pediatrics Ltd. Collaborators: Medpace, Inc.
Conditions	Angelman Syndrome
Enrollment	165 participants
Start Date	2026-06
Primary Completion	2029-03 (estimated)
Study Completion	2031-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-28